Kuriakose CK, Chandiraseharan VK, John AO, Bal D, Jeyaseelan V, Sudarsanam TD. End-of-life decisions: A retrospective study in a tertiary care teaching hospital in India. Indian J Med Res. 2019 Dec;150(6):598-605. doi: 10.4103/ijmr.IJMR_1409_17. PMID: 32048623; PMCID: PMC7038812.

Janeela MA, Oommen A, Misra AK, Ramya I. Paraquat poisoning: Case report of a survivor. J Family Med Prim Care. 2017 Jul-Sep;6(3):672-673. doi: 10.4103/2249-4863.222042. PMID: 29417032; PMCID: PMC5787979.

John AO, Paul H, Vijayakumar S, Anandan S, Sudarsan T, Abraham OC, Balaji V. Mortality from acinetobacter infections as compared to other infections among critically ill patients in South India: A prospective cohort study. Indian J Med Microbiol. 2020 Jan-Mar;38(1):24-31. doi: 10.4103/ijmm.IJMM_19_492. PMID: 32719205.

Manesh A, John AO, Mathew B, Varghese L, Rupa V, Zachariah A, Varghese GM. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Mycoses. 2016 Dec;59(12):765-772. doi: 10.1111/myc.12529. Epub 2016 Jul 22. PMID: 27443253.

Georgy JT, Singh A, John AO, Joel A, Andrews AG, Thumaty DB, Rebekah G, Sigamani E, Chandramohan J, Manipadam MT, Cherian AJ, Abraham DT, Paul MJ, Balakrishnan R, Backianathan S, Chacko RT. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy. Klin Onkol. 2021 Winter;34(1):49-55. English. doi: 10.48095/ccko202149. PMID: 33657819.

Mathew N, Joel A, Andrews AG, John AO, Singh A. CDK 4/6 inhibitor induced lung injury: a case report and review of literature. Ecancermedicalscience. 2021 Jun 7;15:1245. doi: 10.3332/ecancer.2021.1245. PMID: 34267801; PMCID: PMC8241445.

Kuriakose CK, Chandiraseharan VK, John AO, Bal D, Jeyaseelan V, Sudarsanam TD. End-of-life decisions: A retrospective study in a tertiary care teaching hospital in India. Indian J Med Res. 2019 Dec;150(6):598-605. doi: 10.4103/ijmr.IJMR_1409_17. PMID: 32048623; PMCID: PMC7038812.

Janeela MA, Oommen A, Misra AK, Ramya I. Paraquat poisoning: Case report of a survivor. J Family Med Prim Care. 2017 Jul-Sep;6(3):672-673. doi: 10.4103/2249-4863.222042. PMID: 29417032; PMCID: PMC5787979.

John AO, Paul H, Vijayakumar S, Anandan S, Sudarsan T, Abraham OC, Balaji V. Mortality from acinetobacter infections as compared to other infections among critically ill patients in South India: A prospective cohort study. Indian J Med Microbiol. 2020 Jan-Mar;38(1):24-31. doi: 10.4103/ijmm.IJMM_19_492. PMID: 32719205.

Manesh A, John AO, Mathew B, Varghese L, Rupa V, Zachariah A, Varghese GM. Posaconazole: an emerging therapeutic option for invasive rhino-orbito-cerebral mucormycosis. Mycoses. 2016 Dec;59(12):765-772. doi: 10.1111/myc.12529. Epub 2016 Jul 22. PMID: 27443253.

Georgy JT, Singh A, John AO, Joel A, Andrews AG, Thumaty DB, Rebekah G, Sigamani E, Chandramohan J, Manipadam MT, Cherian AJ, Abraham DT, Paul MJ, Balakrishnan R, Backianathan S, Chacko RT. Pathological response and clinical outcomes in operable triple-negative breast cancer with cisplatin added to standard neoadjuvant chemotherapy. Klin Onkol. 2021 Winter;34(1):49-55. English. doi: 10.48095/ccko202149. PMID: 33657819.

Mathew N, Joel A, Andrews AG, John AO, Singh A. CDK 4/6 inhibitor induced lung injury: a case report and review of literature. Ecancermedicalscience. 2021 Jun 7;15:1245. doi: 10.3332/ecancer.2021.1245. PMID: 34267801; PMCID: PMC8241445.

Thomas Z, Jambunathan P, Jibi A, John AO, Singh A. Low-dose nivolumab and cabozantinib in recurrent intestinal-type papillary adenocarcinoma of the sinonasal region. BMJ Case Rep. 2023 Nov 3;16(11):e255021. doi: 10.1136/bcr-2023-255021. PMID: 37923331; PMCID: PMC10626912.

Singh A, Georgy JT, Joel A, Thumaty DB, John AO, Ramnath N, George TK, Sharma P, Patole S, Rebekah G, Sigamani E, Manipadam MT, Cherian AJ, Abraham DT, Paul MJ, Balakrishnan R, Sebastian P, Backianathan S, Chacko RT. Dose-Dense Docetaxel-Cyclophosphamide and Epirubicin-Cisplatin(ddDCEP): Analysis of an Alternative Platinum-Containing Regimen in 116 Patients with Early Triple Negative Breast Cancer. Cancer Invest. 2023 Oct;41(9):789-802. doi: 10.1080/07357907.2023.2278048. Epub 2023 Nov 17. PMID: 37909664.

John AO, Ramnath N. Neoadjuvant Versus Adjuvant Systemic Therapy for Early-Stage Non-Small Cell Lung Cancer: The Changing Landscape Due to Immunotherapy. Oncologist. 2023 Sep 7;28(9):752-764. doi: 10.1093/oncolo/oyad125. PMID: 37338126; PMCID: PMC10485299.

Sebastian R, Georgy JT, George A, Santhanam P, Philip R, Joel A, John AO, Philip DSJ, Thumaty DB, Kodiatte TA, Singh A, Pai R. Real world outcomes with Tepotinib in a series of Indian patients with MET exon 14 skipping positive non-small cell lung cancer. Ecancermedicalscience. 2025 Aug 15;19:1966. doi: 10.3332/ecancer.2025.1966. PMID: 41333367; PMCID: PMC12665903.

Georgy JT, Regi SS, Georgy RV, Sasidharan BK, Joel A, Philip DSJ, John AO, Thumaty DB, Marimuthu PK, Jambunathan P, Harikrishna K, Thomas Z, Rani NJ, Tirkey AJ, Thomas M, Isiah R, Singh A. Low-dose nivolumab plus induction chemotherapy for locally advanced or unresectable head and neck cancer is associated with high response rates and conversion to definitive therapy. Sci Rep. 2025 Oct 8;15(1):35110. doi: 10.1038/s41598-025-19197-y. PMID: 41062634; PMCID: PMC12508025.

Marimuthu PK, Georgy JT, Philip DSJ, John AO, Joel A, Thumaty DB, Chacko RT, Jambunathan P, Thomas Z, Harikrishna K, Isiah R, Pavamani SP, Sasidharan B, Mathew M, Alex Kodiatte T, Irodi A, Thangakunam B, Isaac BTJ, Gupta R, Rani J, Singh A. Real-World Outcomes of Induction Chemotherapy With or Without Low-Dose Nivolumab for Stage III Non-Small Cell Lung Cancer Ineligible for Up-Front Local Therapy: A Propensity Score-Matched Analysis. JCO Glob Oncol. 2025 Mar;11:e2400256. doi: 10.1200/GO-24-00256. Epub 2025 Mar 24. PMID: 40127380.